JP2011505798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505798A5 JP2011505798A5 JP2010536479A JP2010536479A JP2011505798A5 JP 2011505798 A5 JP2011505798 A5 JP 2011505798A5 JP 2010536479 A JP2010536479 A JP 2010536479A JP 2010536479 A JP2010536479 A JP 2010536479A JP 2011505798 A5 JP2011505798 A5 JP 2011505798A5
- Authority
- JP
- Japan
- Prior art keywords
- oligomer
- mcl1
- nucleotide sequence
- cell
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 20
- 239000002773 nucleotide Substances 0.000 claims 16
- 101150094281 mcl1 gene Proteins 0.000 claims 10
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000008585 mastocytosis Diseases 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 239000012664 BCL-2-inhibitor Substances 0.000 claims 1
- 101150017888 Bcl2 gene Proteins 0.000 claims 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1219107P | 2007-12-07 | 2007-12-07 | |
| US9595508P | 2008-09-11 | 2008-09-11 | |
| PCT/EP2008/066920 WO2009071680A2 (en) | 2007-12-07 | 2008-12-05 | Rna antagonist compounds for the modulation of mcl-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011505798A JP2011505798A (ja) | 2011-03-03 |
| JP2011505798A5 true JP2011505798A5 (enExample) | 2012-01-26 |
Family
ID=40329152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010536479A Withdrawn JP2011505798A (ja) | 2007-12-07 | 2008-12-05 | Ｍｃｌ−１を調節するためのＲＮＡアンタゴニスト化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20100323967A1 (enExample) |
| EP (1) | EP2238249A2 (enExample) |
| JP (1) | JP2011505798A (enExample) |
| WO (1) | WO2009071680A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105247052A (zh) * | 2013-05-24 | 2016-01-13 | 罗氏创新中心哥本哈根有限公司 | B-细胞cll/淋巴瘤11a(bcl11a)的寡核苷酸调节剂及其用途 |
| WO2017184082A1 (en) * | 2016-04-22 | 2017-10-26 | Nanyang Technological University | A lymphocyte permeating chimeric oligonucleotide, methods and uses thereof |
| WO2018050801A1 (en) * | 2016-09-16 | 2018-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
| EP3603648B1 (en) | 2017-03-29 | 2025-09-17 | Shionogi & Co., Ltd | Complex of nucleic acid medicine and multibranched lipid |
| JP7692829B2 (ja) | 2019-07-30 | 2025-06-16 | 塩野義製薬株式会社 | Ｍｕｒｆ１を標的とする核酸医薬 |
| JP7751302B2 (ja) | 2020-06-15 | 2025-10-08 | リードファーマ株式会社 | 架橋型ヌクレオシドおよびヌクレオチド |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0856579A1 (en) * | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | An antisense oligonucleotide preparation method |
| GB9711919D0 (en) * | 1997-06-09 | 1997-08-06 | Ciba Geigy Ag | Oligonucleotide derivatives |
| US7217807B2 (en) * | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| EP2013345A2 (en) * | 2006-03-16 | 2009-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of mcl-1 expression |
| CA3044969A1 (en) * | 2006-05-05 | 2007-12-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
-
2008
- 2008-12-05 US US12/746,745 patent/US20100323967A1/en not_active Abandoned
- 2008-12-05 JP JP2010536479A patent/JP2011505798A/ja not_active Withdrawn
- 2008-12-05 EP EP08855783A patent/EP2238249A2/en not_active Withdrawn
- 2008-12-05 WO PCT/EP2008/066920 patent/WO2009071680A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2566724C9 (ru) | Композиции и способы модуляции smn2 сплайсинга у субъекта | |
| JP6944942B2 (ja) | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 | |
| TW201920227A (zh) | 用於抑制脂蛋白元C-III (APOC3)表現之RNAi試劑及組合物 | |
| JP7049262B2 (ja) | 結合組織成長因子を標的とするｒｎａ複合体を用いた特発性肺胞線維症の治療 | |
| JP2011504362A5 (enExample) | ||
| US20210145852A1 (en) | Combination Therapies for Treating Muscular Dystrophy | |
| JP2015518710A (ja) | ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法 | |
| KR20160074368A (ko) | Utrn 발현을 조절하기 위한 조성물 및 방법 | |
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| JP2015523855A (ja) | Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法 | |
| JP2015518712A (ja) | Ｍｅｃｐ２発現を調節するための組成物及び方法 | |
| JP2015523854A5 (enExample) | ||
| JP2016531570A (ja) | ユークロマチン領域を標的とするオリゴヌクレオチド | |
| JP2016521556A (ja) | Ｆｏｘｐ３発現を調節するための組成物及び方法 | |
| JP2016513976A5 (enExample) | ||
| JP2015523853A (ja) | Ａｔｐ２ａ２発現を調節するための組成物及び方法 | |
| WO2019067975A1 (en) | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY | |
| US20160130582A1 (en) | Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof | |
| JP2015518711A (ja) | Ｂｄｎｆ発現を調節するための組成物及び方法 | |
| US20130345288A1 (en) | Inhibitors of the mir-15 family of micro-rnas | |
| JP2012522509A (ja) | コレステロール関連障害の治療におけるｍｉｒ−３３マイクロｒｎａの調節 | |
| JP2011505798A5 (enExample) | ||
| EP3687519A1 (en) | Combination therapies for treating muscular dystrophy | |
| US20200362342A1 (en) | Therapeutic Targeting of a microRNA to Treat Duchenne Muscular Dystrophy | |
| JP2006141402A5 (enExample) |